Akebia Therapeutics, Inc. affirmed revenue guidance for the year 2022. For the year, the company affirm 2022 net product revenue guidance for Auryxia of $170 million - $175 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | +0.92% | -4.35% | -11.29% |
09/05 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.29% | 231M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2022